Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Gleevec: Gastrointestinal Stromal Tumors with KIT stated without a specific alteration (adjuvant) after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)

Broader topic: Gastrointestinal Stromal Tumors

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
adjuvant
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    KIT
    alteration
    stated without a specific alteration
    status
    present
prior therapy
  1. class
    following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors
    status
    required
derivation status
source-attested
derivation note
Scoped from the FDA approved indication for Gleevec (imatinib mesylate) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
source wording
Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)

Study evidence for this setting

1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

NCT00028002 · Source cited / selected · Scope: unclear

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

4 outcome links · 1 safety-group records · 1 quality-of-life measures

→
Source relationships and population-mapping limitations
bindings
    mappings

      Download this complete draft source relationship record →

      Preserved source evidence · Not medical advice